替米沙坦结合常规抗凝治疗对AMI伴高血压患者的疗效

doi:10.3760/cma.j.issn.1007-1245.2023.19.018

摘要/Abstract

摘要：

目的　观察替米沙坦结合常规抗凝治疗改善急性心肌梗死（AMI）伴高血压患者临床特征及心功能的效果。方法　本文为随机对照试验，病例纳入时间为2021年1月至2023年2月，研究对象为南阳市第一人民医院收治的123例AMI伴高血压患者，采用随机数字表法将入组患者分为两组，分别列为观察组（62例）和对照组（61例）。观察组中男32例，女30例，年龄（60.44±5.27）岁；对照组中男33例，女28例，年龄（61.25±5.16）岁。对照组仅接受常规抗凝治疗，观察组采用替米沙坦结合常规抗凝治疗，比较两组患者治疗前后的血压水平、心血管内皮功能、心功能指标变化情况及用药安全性。采用χ²检验、t检验。结果　治疗后，观察组的收缩压为（115.25±20.33）mmHg（1 mmHg=0.133 kPa），舒张压为（80.25±10.61）mmHg，均低于对照组［（130.27±20.16）mmHg、（87.62±10.24）mmHg］，差异均有统计学意义（均P<0.05）。治疗后，观察组的血流介导下血管扩张程度（FMD）为（12.21±3.16）%，硝酸甘油介导下血管内皮舒张程度（NMD）为（9.44±2.16）%，均高于对照组［（10.45±3.28）%、（8.76±2.15）%］，脉搏波传导速度（PWV）为（10.33±3.26）m/s，低于对照组（12.28±3.15）m/s，差异均有统计学意义（均P<0.05）。治疗后，观察组的左心室射血分数（LVEF）为（55.25±10.27）%，高于对照组（49.36±10.27）%，左心室舒张末期内径（LVDD）为（40.33±10.27）mm，左心室后壁厚度（LVPW）为（9.52±3.46）mm，均低于对照组［（46.62±10.31）mm、（11.45±3.46）mm］，差异均有统计学意义（均P<0.05）。治疗后，观察组的药物相关不良反应发生率为6.45%（4/62），略高于对照组4.92%（3/61），差异无统计学意义（P>0.05）。结论　替米沙坦联合常规抗凝治疗能下调AMI伴高血压患者的血压水平，对改善患者心血管内皮功能、心功能均有积极意义，联合应用此药未明显增加患者的药物相关不良反应发生风险，安全性较高。

关键词:

急性心肌梗死, 高血压, 替米沙坦, 抗凝治疗, 心功能

Abstract:

Objective　To observe the effect of telmisartan combined with conventional anticoagulant therapy on improving clinical features and cardiac function in patients with acute myocardial infarction (AMI) and hypertension. Methods　This was a randomized controlled trial. A total of 123 AMI patients with hypertension admitted to Nanyang First People's Hospital from January 2021 to February 2023 were divided into two groups by the random number table method, with 62 cases in the observation group and 61 cases in the control group. In the observation group, there were 32 males and 30 females, aged (60.44±5.27) years. In the control group, there were 33 males and 28 females, aged (61.25±5.16) years. The control group only received conventional anticoagulation treatment, and the observation group received telmisartan combined with conventional anticoagulation treatment. The changes in blood pressure levels, cardiovascular endothelial function, and cardiac function indicators before and after treatment and medication safety were compared between the two groups. χ² test and t test were used. Results　After treatment, the systolic blood pressure and diastolic blood pressure in the observation group were (115.25±20.33) mmHg (1 mmHg = 0.133 kPa) and (80.25±10.61) mmHg, which were both lower than those in the control group [(130.27±20.16) mmHg and (87.62±10.24) mmHg], with statistically significant differences (both P<0.05). After treatment, the blood flow mediated vasodilation (FMD) of the observation group was (12.21±3.16)%, and the nitroglycerin mediated vasodilation (NMD) was (9.44±2.16)%, which were both higher than those of the control group [(10.45±3.28)% and (8.76±2.15)%]; the pulse wave velocity (PWV) was (10.33±3.26) m/s, which was lower than that of the control group [(12.28±3.15) m/s], with statistically significant differences (all P<0.05). After treatment, the left ventricular ejection fraction (LVEF) of the observation group was (55.25±10.27)%, which was higher than that of the control group [(49.36±10.27)%]; the left ventricular end-diastolic diameter (LVDD) was (40.33±10.27) mm, and the left ventricular posterior wall thickness (LVPW) was (9.52±3.46) mm, which were lower than those of the control group [(46.62±10.31) mm and (11.45±3.46) mm], with statistically significant differences (all P<0.05). After treatment, the incidence of drug-related adverse reactions in the observation group was 6.45% (4/62), which was slightly higher than that in the control group [4.92% (3/61)], with no statistically significant difference (P>0.05). Conclusions　Telmisartan combined with conventional anticoagulant therapy can lower the blood pressure level in patients with AMI and hypertension, and has positive significance in improving their cardiovascular endothelial function and cardiac function. The combined use of this drug does not significantly increase the risk of drug-related adverse reactions in patients, with high safety.

Key words:

Acute myocardial infarction, Hypertension, Telmisartan, Anticoagulant therapy, Cardiac function

冯红亚.

替米沙坦结合常规抗凝治疗对AMI伴高血压患者的疗效 [J]. 国际医药卫生导报, 2023, 29(19): 2745-2749.

Feng Hongya.

Efficacy of telmisartan combined with conventional anticoagulant therapy in AMI patients with hypertension [J]. International Medicine and Health Guidance News, 2023, 29(19): 2745-2749.

参考文献

[1] 孙晓晖,段海平,余灿清,等.2014-2020年青岛市急性心肌梗死发病率、死亡率特征及疾病负担分析[J].中华流行病学杂志,2023,44(2):250-256. DOI:10.3760/cma.j.cn112338-20220825-00733.
[2] 李爱珍,王风燕,王红丽,等.青年急性心肌梗死患者的临床特点和危险因素分析[J].中国实验诊断学,2022,26(4):553-555. DOI:10.3969/j.issn.1007-4287.2022.04.023.
[3] 方倩.PCI联合冠脉内注射重组人尿激酶原溶栓对急性心肌梗死患者的预后影响研究[J].罕少疾病杂志,2023,30(2):39-40. DOI:10.3969/j.issn.1009-3257.2023.02.017.
[4] 冉晨光,韩佳,赵娜.比伐卢定联合挽救性PCI治疗老年急性心肌梗死溶栓失败患者的疗效及预后评价[J].临床和实验医学杂志,2022,21(7):699-702. DOI:10.3969/j.issn.1671-4695.2022.07.007.
[5] Yan J, Zhou J, Huang J, et al. The outcomes of acute myocardial infarction patients comorbidity with hypertension and hyperhomocysteinemia[J]. Sci Rep, 2021, 11(1):22936. DOI: 10.1038/s41598-021-02340-w.
[6] 袁颖,曲超,刘营营,等.替米沙坦联合β受体阻滞剂、血管紧张素转换酶抑制剂类药物治疗急性心肌梗死伴高血压的效果[J].中国当代医药,2023,30(1):83-86. DOI:10.3969/j.issn.1674-4721.2023.01.021.
[7] 赵静,赵淑清.老年高血压病患者脂质代谢异常及其与心血管疾病发生风险的相关性分析[J].老年医学与保健,2022,28(3):544-548. DOI:10.3969/j.issn.1008-8296.2022. 03.019.
[8] Milwidsky A, Greidinger D, Frydman S, et al. Echocardiographic Killip Classification[J]. J Am Soc Echocardiogr, 2022, 35(3):287-294. DOI: 10.1016/j.echo.2021.10.012.
[9] 廖鹏达,李慧,郭力恒,等.«急性心肌梗死中西医结合诊疗指南»制定的思考[J].中国中西医结合杂志,2022,42(7):873-876. DOI:10.7661/j.cjim.20210802.095.
[10] 彭齐,杨琴,胡国智,等.有氧运动改善急性心肌梗死伴心衰患者心功能、血管内皮功能及生存质量的价值观察[J].中国急救复苏与灾害医学杂志,2023,18(3):298-301. DOI:10.3969/j.issn.1673-6966.2023.03.006.
[11] Kapur NK, Thayer KL, Zweck E. Cardiogenic shock in the setting of acute myocardial infarction[J]. Methodist Debakey Cardiovasc J, 2020, 16(1):16-21. DOI: 10.14797/mdcj-16-1-16.
[12] 赵亮亮.标准化肝素抗凝治疗方案在急性心肌梗死溶栓患者中的应用效果及并发症分析[J].中国标准化,2021(4):97-99.
[13] 李秀芬,姜述斌,路璐,等.比伐芦定和替罗非班在急性ST段抬高型心肌梗死患者行急诊经皮冠状动脉介入术中的抗凝效果比较[J].中国医药,2021,16(2):188-192. DOI:10.3760/j.issn.1673-4777.2021.02.007.
[14] 蒋子裕,陈楚雯,杨伟烙,等.原发性高血压伴心肌梗死患者血压变异性、颈动脉内中膜厚度与冠状动脉病变严重程度相关性的临床研究[J].医学综述,2019,25(23):4812-4816,封3. DOI:10.3969/j.issn.1006-2084.2019. 23.042.
[15] 谢静,阿米娜·达伍提,阿那古丽·阿不力米提,等.血清SFRP5、sMFAP4水平与急性心肌梗死伴高血压患者PCI后支架内再狭窄的关系[J].山东医药,2023,63(1):51-55. DOI:10.3969/j.issn.1002-266X.2023.01.012.
[16] Chang D, Xu TT, Zhang SJ, et al. Telmisartan ameliorates cardiac fibrosis and diastolic function in cardiorenal heart failure with preserved ejection fraction[J]. Exp Biol Med (Maywood), 2021, 246(23):2511-2521. DOI: 10.1177/15353702211035058.
[17] 魏留军,高航.替米沙坦联合硝苯地平控释片治疗冠心病伴轻度高血压的效果及对血管内皮功能的影响[J].中国实用医药,2021,16(19):156-158. DOI:10.14163/j.cnki.11- 5547/r.2021.19.057.
[18] Ward JL, Guillot E, Domenig O, et al. Circulating renin-angiotensin-aldosterone system activity in cats with systemic hypertension or cardiomyopathy[J]. J Vet Intern Med, 2022, 36(3):897-909. DOI: 10.1111/jvim.16401.
[19] 郭骏.替米沙坦与依那普利对冠心病合并糖尿病肾病患者心室重构和肾脏预后的价值[J].中国处方药,2019,17(9):75-76. DOI:10.3969/j.issn.1671-945X.2019.09.041.
[20] 秘钧,李世鹏.替米沙坦辅助治疗高血压合并冠心病的疗效及对其血压、血脂、左心室功能的影响[J].四川生理科学杂志,2021,43(10):1674-1676.